Alkermes said on Monday that it has appointed Mark Namchuk to be senior vice president of research, pharmaceutical and nonclinical development.
“Dr. Namchuk brings a wealth of valuable drug discovery and development expertise to our team, which will help to further strengthen our increasingly robust product pipeline,” Richard Pops, chief executive officer of Alkermes, said. “We look forward to his contributions and drug development insights as we create innovative new medicines and design studies to demonstrate their differentiated properties in addressing patient needs.”
Namchuk will be in charge of managing the company`s early-stage product pipeline and will serve on Alkermes’ executive management team. Namchuk said it is an exciting time to be a part of Alkermes amid the promising programs the company has underway.
“I look forward to helping advance our current priority drug candidates for CNS diseases and guiding our pharmaceutical development strategy for the future,” Namchuk said.
Namchuk has almost 20 years of experience in integrated drug and research-and-development discovery, and most recently has served as senior vice president and interim global head of research for Vertex Pharmaceuticals. At Vertex, Namchuk led a group of over 450 researchers in discovering transformative medicines in the areas of cystic fibrosis, neurology, inflammatory diseases, oncology and infectious diseases.